Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily used for managing type 2 diabetes, whereas Wegovy is specifically approved for weight loss.

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide. These complications are potentially separate from the toxic effect of the drugs, according to the study published in JAMA Ophthalmology. 1

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular (CV) and kidney disease risks.

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started a side hustle to afford it.

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like Ozempic.

An Air Force F-35 fighter jet crashed on Tuesday during a training mission in central Alaska. Officials say the crash happened during the landing phase. After ejecting from the jet, they say the pilot was taken to a medical facility for evaluation.

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, potentially leading to serious health complications over time. Experts call for more research and a cautious approach to using these drugs,

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential impact on CKD.

Utah Facial Plastics is transforming weight loss with Semaglutide and Tirzepitide, two proven treatments that help regulate appetite, improve insulin

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 billion and impressive revenue growth of 26.